Clostridium butyricum MIYAIRI 588

Clostridium butyricum MIYAIRI 588 is a spore-forming probiotic strain that produces butyric acid in the colon to support digestive health and immune function. This beneficial bacterium strengthens the intestinal barrier and modulates inflammatory responses through short-chain fatty acid production.

Origin & History

Clostridium butyricum is a spore-forming bacterium naturally found in the human gut and soil. It is cultured for use in supplements to support digestive health and balance gut flora.

Historical & Cultural Context

Clostridium butyricum has been used in traditional Asian medicine for its digestive benefits and is now gaining popularity in Western probiotic formulations.

Health Benefits

- Enhances gut health by producing butyric acid, which nourishes colon cells and improves bowel regularity. This promotes a healthy digestive system. - Reduces inflammation by modulating immune responses, potentially lowering the risk of chronic inflammatory diseases. - Supports metabolic health by influencing fat metabolism, which can aid in weight management. - Boosts immune function by stimulating the production of beneficial short-chain fatty acids, enhancing the body's defense mechanisms. - Improves mental clarity by interacting with the gut-brain axis, potentially reducing symptoms of anxiety and depression. - Supports liver health by reducing liver fat accumulation, promoting detoxification processes. - Enhances skin health by reducing systemic inflammation, leading to clearer, more radiant skin.

How It Works

Clostridium butyricum MIYAIRI 588 ferments dietary fiber to produce butyric acid, which serves as the primary energy source for colonocytes and strengthens tight junction proteins in the intestinal barrier. Butyric acid activates GPR41 and GPR43 receptors on immune cells, promoting regulatory T-cell differentiation and reducing pro-inflammatory cytokine production. The strain also produces vitamin B12 and competes with pathogenic bacteria for colonization sites.

Scientific Research

Research, including RCTs, indicates that Clostridium butyricum can help improve gut health and treat conditions like irritable bowel syndrome and ulcerative colitis.

Clinical Summary

Human studies with Clostridium butyricum MIYAIRI 588 include randomized controlled trials in patients with irritable bowel syndrome and antibiotic-associated diarrhea. A 12-week study of 60 IBS patients showed 40% improvement in abdominal pain scores compared to placebo. Research in elderly patients demonstrated reduced duration of antibiotic-associated diarrhea from 5.2 to 2.8 days. However, most clinical evidence comes from small-scale studies, and larger trials are needed to confirm therapeutic benefits.

Preparation & Dosage

Consult a healthcare provider for appropriate dosage recommendations.

Synergy & Pairings

Lactobacillus casei, Bifidobacterium lactis, Inulin

Safety & Interactions

Clostridium butyricum MIYAIRI 588 is generally well-tolerated with mild gastrointestinal symptoms like bloating or gas being the most common side effects. The strain may theoretically interact with broad-spectrum antibiotics, which could reduce probiotic viability. Immunocompromised individuals should consult healthcare providers before use due to potential risk of bacteremia. Safety during pregnancy and breastfeeding has not been established through clinical trials.